MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies

doi:10.1002/med.21799

	MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies
	Liang, Xuewu 3; Cao, YiChun 1; Li, Chunpu 3; Yu, Haolan 2; Yang, Chenghua 2; Liu, Hong 3
刊名	MEDICINAL RESEARCH REVIEWS
	2021-03-25
页码	35
关键词	DLBCL MALT lymphoma MALT1 MALT1 inhibitors NF‐ κ B pathway
ISSN号	0198-6325
DOI	10.1002/med.21799
通讯作者	Yang, Chenghua(chenghua-yang@qq.com) ; Liu, Hong(hliu@simm.ac.cn)
英文摘要	Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key adaptor protein that regulates the NF-kappa B pathway, in which MALT1 functions as a scaffold protein and protease to trigger downstream signals. The abnormal expression of MALT1 is closely associated with lymphomagenesis and other diseases, including solid tumors and autoimmune diseases. MALT1 is the only protease in the underlying pathogenesis of these diseases, and its proteolytic activity can be pharmacologically regulated. Therefore, MALT1 is a potential and promising target for anti-lymphoma and other MALT1-related disease treatments. Currently, the development of MALT1 inhibitors is still in its early stages. This review presents an overview of MALT1, particularly its X-ray structures and biological functions, and elaborates on the pathogenesis of diseases associated with its dysregulation. We then summarize previously reported MALT1 inhibitors, focusing on their molecular structure, biological activity, structure-activity relationship, and limitations. Finally, we propose future research directions to accelerate the discovery of novel MALT1 inhibitors with clinical applications. Overall, this review provides a comprehensive and systematic overview of MALT1-related research advances and serves as a theoretical basis for drug discovery and research.
资助项目	National Natural Science Foundation of China[21907102] ; National Natural Science Foundation of China[21632008] ; National Natural Science Foundation of China[91229204] ; National Natural Science Foundation of China[81473245] ; National Natural Science Foundation of China[81772695]
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	WILEY
WOS记录号	WOS:000632366400001
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/295391]
专题	中国科学院上海药物研究所
通讯作者	Yang, Chenghua; Liu, Hong
作者单位	1.Fudan Univ, Sch Pharm, Shanghai, Peoples R China 2.Second Mil Med Univ, Changhai Hosp, Dept Urol, 168 Chang Hai Rd, Shanghai 200433, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China
推荐引用方式 GB/T 7714	Liang, Xuewu,Cao, YiChun,Li, Chunpu,et al. MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies[J]. MEDICINAL RESEARCH REVIEWS,2021:35.
APA	Liang, Xuewu,Cao, YiChun,Li, Chunpu,Yu, Haolan,Yang, Chenghua,&Liu, Hong.(2021).MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies.MEDICINAL RESEARCH REVIEWS,35.
MLA	Liang, Xuewu,et al."MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies".MEDICINAL RESEARCH REVIEWS (2021):35.